Core Viewpoint - Agilent Technologies reported a strong financial performance for Q4 2025, with revenue of $1.86 billion, a year-over-year increase of 9.4%, and an annual revenue of $6.95 billion, growing by 6.7%. The company expects revenue for 2026 to be between $7.3 billion and $7.4 billion, reflecting a growth of 5% to 7% [1][3][6]. Financial Performance Summary - Q4 2025 revenue reached $1.86 billion, exceeding expectations, with a core growth of 7.2% [4]. - The net profit under GAAP for Q4 was $434 million, with an EPS of $1.53, marking a 25% increase from Q4 2024 [4][7]. - For the entire fiscal year 2025, revenue was $6.95 billion, surpassing expectations, with a reported growth of 6.7% and a core growth of 4.9% [6]. Quarterly Performance Breakdown - Q1 2025: Revenue of $1.68 billion, a 1.4% increase, with LDG business growth of 4% [5]. - Q2 2025: Revenue of $1.67 billion, a 6.0% increase, with a 10% growth in China [5]. - Q3 2025: Revenue of $1.74 billion, with a core growth of 10.1% [5]. - Q4 2025: Revenue of $1.86 billion, a 9.4% increase, with annual revenue exceeding expectations [5]. Business Segment Performance - Life Sciences and Diagnostics Group (LDG) reported Q4 revenue of $755 million, a 15% increase, with a core growth of 11% [10]. - Agilent CrossLab Group (ACG) had Q4 revenue of $755 million, a 7% increase, with a customer satisfaction rate exceeding 90% [11]. - Application Markets Group (AMG) reported Q4 revenue of $351 million, a 4% increase, facing some challenges but showing stability in environmental and food safety sectors [12]. Outlook for 2026 - The company is optimistic about 2026, expecting revenue between $7.3 billion and $7.4 billion, with a core growth of 4% to 6% [13]. - For Q1 2026, revenue is projected to be between $1.79 billion and $1.82 billion, reflecting a year-over-year growth of 6% to 8% [13].

Core Insights - The company is pleased with its execution throughout the year, particularly in fiscal Q3, highlighting successful product launches and a strong replacement cycle [1] - Key product launches include the Pro iQ single-quad and the 8850, which have resonated well in the market [1] - The Infinity III replacement cycle has also contributed positively to the overall performance [1] Services Business - The services business is critical for the company, emphasizing the importance of customer connection and satisfaction in driving performance [2] - Four key areas have been identified as significant contributors to the company's success, with a particular focus on the CDMO business [2]

Core Insights - Agilent Technologies, Inc. is a key player in the life sciences sector, focusing on medical tools and equipment for lab research and diagnostics, with a strong emphasis on innovation and quality [1] Financial Performance - On November 24, 2025, Agilent reported earnings per share (EPS) of $1.59, matching estimates, which is significant for investor behavior and stock price performance [2] - The company's revenues reached approximately $1.84 billion, exceeding the estimated $1.83 billion, reflecting a 7.8% increase from the same quarter last year [2] - Agilent's fourth-quarter revenue was $1.86 billion, surpassing guidance and marking a 9.4% increase compared to the same period in 2024 [3] - The core growth rate was 7.2%, driven by strong demand for Agilent's products [3] - GAAP net income for the quarter was $434 million, or $1.53 per share, an increase from $351 million, or $1.22 per share, in the previous year [3] - Non-GAAP net income reached $452 million, or $1.59 per share, indicating robust financial performance [4] Valuation Metrics - The price-to-earnings (P/E) ratio is approximately 35.88, reflecting investor confidence in Agilent's earnings potential [4] - The price-to-sales ratio stands at about 6.42, indicating the company's market value relative to its sales [4] - Financial metrics include an enterprise value to sales ratio of 6.69 and an enterprise value to operating cash flow ratio of 30.38, providing insights into valuation [5] - The earnings yield is about 2.79%, offering a perspective on return on investment [5] - Agilent has a debt-to-equity ratio of 0.54 and a current ratio of 2.25, demonstrating a balanced financial structure and strong liquidity [5]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

分组1 - Agilent Technologies reported quarterly earnings of $1.59 per share, matching the Zacks Consensus Estimate, and showing an increase from $1.46 per share a year ago [1] - The company posted revenues of $1.86 billion for the quarter ended October 2025, exceeding the Zacks Consensus Estimate by 1.49%, compared to $1.7 billion in the same quarter last year [2] - Agilent has surpassed consensus EPS estimates three times and revenue estimates four times over the last four quarters [1][2] 分组2 - The stock has gained approximately 12.6% since the beginning of the year, slightly outperforming the S&P 500's gain of 12.3% [3] - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $1.41 for the coming quarter and $5.98 for the current fiscal year [4][7] - The Zacks Industry Rank places the Medical - Products sector in the bottom 36% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Financial Data and Key Metrics Changes - Agilent reported Q4 revenue of $1.86 billion, growing 7.2% on a core basis, marking the sixth consecutive quarter of core growth acceleration [8][28] - Q4 earnings per share were $1.59, above the midpoint of guidance and grew 9% year-over-year [31] - Gross margins improved sequentially by 100 basis points to 54.1%, though down 100 basis points year-over-year due to tariff headwinds [30] - Operating margins were 27.2%, up more than 200 basis points sequentially, driven by volume leverage and strong pricing [30] Business Line Data and Key Metrics Changes - Life Sciences and Diagnostics Group (LDG) grew 11%, driven by strong performance in LC and LCMS instruments and robust CDMO results [29] - Applied Markets Group (AMG) grew 3%, led by high single-digit growth in GC and GCMS [29] - Agilent CrossLab Group (ACG) grew 6%, with high single-digit growth in the rest of the world offset by mid-single-digit declines in China [29] Market Data and Key Metrics Changes - Pharma market grew 12% in Q4, with biotech spending increasing in the low 20s [18][19] - Chemical and advanced materials grew 7%, driven by strong demand in the Americas and Europe [20] - Diagnostics and clinical grew 7%, with potential upside from new product offerings [20] - Academia and government, the smallest end market, declined 10% due to federal spending reductions [21] Company Strategy and Development Direction - The company emphasizes innovative products and services, customer intimacy, increased capabilities, and the Ignite operating system to drive long-term growth [10][15] - Focus on AI to enhance operational efficiency and product development, with AI generating 80% of engineering drawings [12][14] - Plans to advance the Ignite operating system, sharpen commercial execution, and capture opportunities from improving end markets [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in pharma and biotech markets, with expectations for continued growth in specialty CDMO services [23][24] - The company anticipates 4%-6% core growth for FY2026, driven by instrument replacement cycles and demand for specialty CDMO services [24][26] - Management highlighted the importance of reshoring in pharma, estimating a $1 billion opportunity by 2030 [60][61] Other Important Information - The company plans to invest $500 million in capital expenditures and expects operating cash flow to be in the range of $1.6 billion-$1.7 billion [35] - The company increased its dividend by 3%, reflecting strong financial discipline [31] Q&A Session Summary Question: Comment on BioVectra performance and CapEx increase - Management expressed satisfaction with BioVectra's performance, driven by GLP business, and noted the $100 million CapEx increase is focused on NASD capacity and consumable expansion [39][41] Question: Discuss margin guidance and potential for improvement - Management indicated a prudent margin guidance for 2026, driven by Ignite pricing optimization and operational efficiencies, with potential for better margins if top-line performance exceeds expectations [42][43] Question: Insights on biopharma customer sentiment and budget flush - Management noted a 12% growth in pharma and low double-digit growth in biotech, with expectations for a more typical year-end budget flush [49][50] Question: Visibility on NASD business and capacity expansion - Management confirmed a robust order book for NASD and discussed the timeline for capacity expansion, indicating strong market positioning [52][54] Question: Performance in China and impact of federal spending - Management reported a 4% decline in China, attributing it to federal spending reductions and mixed performance across end markets [56][58] Question: Growth outlook for GLP-1 business and competitive positioning - Management highlighted GLP-1 revenue growth, with significant contributions from both CDMO and analytical tools, and expressed confidence in capturing market share in India [64][66] Question: Academic and government market performance - Management acknowledged a 10% decline in the academic and government market, primarily due to U.S. federal spending reductions, and expects continued softness in FY2026 [70]

Financial Data and Key Metrics Changes - Agilent reported Q4 revenue of $1.86 billion, growing 7.2% on a core basis, marking the sixth consecutive quarter of core growth acceleration [8][28] - Earnings per share for the quarter was $1.59, above the midpoint of guidance and reflecting a 9% year-over-year growth [31] - Gross margins improved sequentially by 100 basis points to 54.1%, although down 100 basis points year-over-year due to tariff headwinds [30] Business Segment Data and Key Metrics Changes - Life Sciences and Diagnostics Group (LDG) grew 11%, driven by strong performance in LC and LCMS instruments and robust CDMO results [29] - Applied Markets Group (AMG) grew 3%, led by high single-digit growth in GC and GCMS [29] - Agilent CrossLab Group (ACG) grew 6%, with high single-digit growth in the rest of the world offset by mid-single-digit declines in China [29] Market Data and Key Metrics Changes - The pharma market saw a 12% growth, with biotech spending growing in the low 20s during the quarter [18][19] - Chemical and advanced materials grew 7%, driven by strong demand in the Americas and Europe [20] - Diagnostics and clinical grew 7%, while environmental and forensics grew 9% [20] Company Strategy and Development Direction - Agilent's strategy focuses on innovative products and services, customer intimacy, increased capabilities, and the Ignite Operating System to drive long-term growth [10][15] - The company aims to advance its Ignite operating system, sharpen commercial execution, and capture opportunities from improving end markets [22][24] - Agilent anticipates 4%-6% core growth for FY2026, supported by structural growth drivers and a focus on instrument replacement cycles [24][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the improving pharma market and the potential for reshoring in the pharmaceutical sector [23][60] - The company expects to deliver 75 basis points of operating margin expansion in FY2026, with a focus on innovation and strategic capacity expansion [25][26] - Management highlighted the importance of customer relationships and the positive impact of recent product innovations on future growth [50][66] Other Important Information - Agilent's Ignite Operating System has already delivered over $150 million in annualized savings and improved operational efficiencies [16][17] - The company is focused on deploying capital where it delivers the highest long-term value, balancing investments in innovation and returning capital to shareholders [26][27] Q&A Session Summary Question: Comments on BIOVECTRA performance and CapEx increase - Management expressed satisfaction with BIOVECTRA's performance, attributing strong results to GLP business and indicating plans for key molecules in 2026 [40] - The $100 million CapEx increase is primarily for NASD capacity and consumable expansion [41] Question: Insights on margins and potential for improvement - Management guided for a 75 basis points margin improvement in 2026, driven by pricing optimization and operational efficiencies [42][43] Question: General tone from biopharma customers - Management noted a 12% growth in pharma and low 20s growth in biotech, indicating improved funding and capital spending among large biotech firms [49][50] Question: Visibility on NASD business and capacity expansion - Management confirmed a robust order book for NASD and indicated that capacity expansions are expected to come online in early to mid-2027 [54] Question: Performance in China and future expectations - Management reported a 4% decline in China, attributing it to various market dynamics and maintaining a stable revenue expectation of around $300 million per quarter [57][58] Question: Growth outlook for GLP-1s and competitive positioning - Management indicated that GLP-1 revenue was approximately $130 million in 2025, with strong growth expected in 2026, particularly in India [64][66] Question: Academic and government market performance - Management reported a 10% decline in the academic and government market, primarily due to U.S. federal spending reductions [70]

Financial Data and Key Metrics Changes - Agilent reported Q4 revenue of $1.86 billion, growing 7.2% on a core basis, marking the sixth consecutive quarter of core growth acceleration [8][27] - Earnings per share for the quarter was $1.59, above the midpoint of guidance and reflecting a 9% year-over-year growth [31] - Gross margins improved sequentially by 100 basis points to 54.1%, although down 100 basis points year-over-year due to tariff headwinds [30] Business Line Data and Key Metrics Changes - Life Sciences and Diagnostics Markets Group (LDG) grew 11%, driven by strong performance in LC and LCMS instruments and robust CDMO results [28] - Applied Markets Group (AMG) grew 3%, led by high single-digit growth in GC and GCMS [28] - Agilent CrossLab Group (ACG) grew 6%, with high single-digit growth in the rest of the world offset by mid-single-digit declines in China [28] Market Data and Key Metrics Changes - The pharma market saw a 12% growth, with biotech spending growing in the low 20s during the quarter [19][24] - Chemical and advanced materials grew 7%, driven by strong demand in the Americas and Europe [20] - Diagnostics and clinical grew 7%, while environmental and forensics grew 9% [20] Company Strategy and Development Direction - Agilent's strategy focuses on innovative products and services, customer intimacy, increased capabilities, and the Ignite operating system to drive long-term growth [10][18] - The company aims to advance its Ignite operating system, sharpen commercial execution, and capture opportunities from improving end markets [23][24] - Agilent anticipates mid-teens growth in specialty CDMO pharma services and continued strength in diagnostics and clinical testing demand [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the improving visibility around pricing and a stabilizing tariff environment, particularly in the pharma sector [24] - The company expects 4%-6% core growth for FY2026, driven by instrument replacement cycles and demand for specialty CDMO services [25][32] - Management highlighted the importance of reshoring in pharma and anticipates a $1 billion addressable market opportunity by 2030 [50] Other Important Information - Operating cash flow for Q4 was $545 million, with $93 million invested in capital expenditures and $85 million in share repurchases [31] - The company increased its dividend by 3%, reflecting strong financial discipline [31] - Agilent's integration of BioVectra is seen as a positive contributor to future growth [39] Q&A Session Summary Question: Comment on BioVectra's performance - Management expressed satisfaction with BioVectra's performance, driven by GLP business, and highlighted strong integration [39] Question: Clarification on margin guidance - Management provided insights on the 75 basis points margin improvement guidance, attributing it to Ignite pricing optimization and operational efficiencies [40] Question: General tone from biopharma customers - Management noted a positive sentiment in pharma, with a 12% growth overall, and indicated that biotech is starting to recover [42] Question: Visibility on NASD business - Management confirmed a robust order book for the NASD business, with capacity expansions planned for 2026 [45][47] Question: Downside variance in China - Management explained that China experienced a 4% decline, with stable contributions around $300 million per quarter, and noted the impact of federal spending reductions [48][49] Question: Growth outlook for GLP-1s - Management indicated that GLP-1 revenue was about $130 million in 2025, with expectations for continued growth in 2026 [51][52] Question: Academic and government market performance - Management reported a 10% decline in the academic and government market, primarily due to U.S. federal spending reductions [53][54]

FINANCIAL RESULTS OVERVIEW 4Q FY2025 November 24, 2025 Thank You for Your Attention Safe Harbor This presentation contains forward- looking statements (including, without limitation, information, and future guidance on the company's revenue, revenue growth, earnings per share, operating cash flow, capital expenditures, net interest and other/expense, impact of acquisitions and related financing, share repurchases, dividends, diluted share counts, and currency exchange rates) that involve risks and uncertain ...

Financial Performance - Revenue for Q4 FY2025 was $1.86 billion, exceeding guidance and representing a growth of 9.4% reported and 7.2% on a core basis compared to Q4 FY2024 [4]. - GAAP net income for Q4 FY2025 was $434 million, with EPS of $1.53, up 25% from Q4 FY2024 [5]. - Non-GAAP net income for Q4 FY2025 was $452 million, with EPS of $1.59, up 9% from Q4 FY2024 [5]. - Total revenue for FY2025 was $6.95 billion, exceeding guidance and representing a growth of 6.7% reported and 4.9% on a core basis compared to FY2024 [4]. - GAAP net income for FY2025 was $1.303 billion, with EPS of $4.57, up 3% from FY2024 [4]. - Non-GAAP net income for FY2025 was $1.592 billion, with EPS of $5.59, up 6% from FY2024 [4]. - FY2026 revenue is expected to be in the range of $7.3 billion to $7.4 billion, representing growth of 5% to 7% reported and 4% to 6% core [4]. - Q1 FY2026 revenue guidance is expected to be in the range of $1.79 billion to $1.82 billion, an increase of 6% to 8% reported and 4% to 6% core [8]. Segment Performance - Life Sciences and Diagnostics Markets Group reported Q4 revenue of $755 million, an increase of 15% reported and 11% core year-over-year [7]. - Agilent CrossLab Group reported Q4 revenue of $755 million, an increase of 7% reported and 6% core year-over-year [7]. - Revenue for the Life Sciences and Diagnostics segment in Q4 2025 was $755 million, a 15% increase from $657 million in Q4 2024 [37]. - Revenue for the Agilent CrossLab segment in Q4 2025 was $755 million, up from $706 million in Q4 2024, representing a growth of 6.9% [38]. - Applied Markets Segment revenue for Q4'25 was $351 million, a 4% increase from $338 million in Q4'24 [39]. - Life Sciences and Diagnostics Markets Segment revenue for FY25 reached $2,726 million, up 11% from $2,466 million in FY24 [47]. - Agilent CrossLab Segment revenue for FY25 was $2,908 million, reflecting a 6% increase from $2,747 million in FY24 [47]. - Non-GAAP revenue for Agilent in Q4'25 was $1,839 million, an 8% increase year-over-year [45]. - Non-GAAP revenue for the Applied Markets Segment in FY25 was $1,314 million, reflecting a 1% increase from FY24 [47]. Margins and Assets - Operating margin for the Life Sciences and Diagnostics segment improved to 22.7% in Q4 2025 from 21.5% in Q4 2024 [37]. - Operating margin for the Agilent CrossLab segment decreased to 32.5% in Q4 2025 from 33.8% in Q4 2024 [38]. - Gross margin for the Life Sciences and Diagnostics Markets Segment decreased to 52.3% in FY25 from 54.5% in FY24 [40]. - Operating margin for the Applied Markets Segment in FY25 was 22.9%, down from 24.0% in FY24 [42]. - The Agilent CrossLab Segment's operating margin decreased to 32.5% in FY25 from 33.7% in FY24 [41]. Balance Sheet Highlights - Total assets increased to $12,727 million in 2025 from $11,846 million in 2024, representing a growth of 7.4% [20]. - Cash and cash equivalents rose to $1,789 million in 2025, up from $1,329 million in 2024, marking a 34.6% increase [20]. - Total current liabilities increased to $2,347 million in 2025 from $1,895 million in 2024, a rise of 23.9% [20]. - Total stockholders' equity grew to $6,741 million in 2025, compared to $5,898 million in 2024, reflecting an increase of 14.3% [20]. - Net income for the fiscal year ended October 31, 2025, was $1,303 million, compared to $1,289 million in 2024, reflecting a growth of 1.1% [24]. - Non-GAAP net income for 2025 was $1,592 million, up from $1,539 million in 2024, indicating a 3.4% increase [24]. Year-over-Year Growth - Year-over-year revenue growth for the Life Sciences and Diagnostics Markets Segment was 12% at constant currency in Q4'25 [45]. - Agilent's total revenue for FY25 was $6,948 million, representing a 7% increase from $6,510 million in FY24 [47].